A schematic

of the training program is displayed below in Figure 1. Figure 1 Resistance Training Protocol. Clinical Laboratory Chemical Analyses Laboratory measures were performed at baseline, and weeks 3, 6 and 9. The tests included a complete blood count (CBC) with differential and platelet count, and a chemistry panel, which included sodium, potassium, chloride, carbon dioxide, calcium, AP, AST, ALT, bilirubin, glucose, blood urea nitrogen, creatinine, albumin, globulin, and estimated glomerular filtration rate, The lipid panel (total cholesterol, HDL- and LDL-cholesterol) was drawn at baseline and GSK1120212 cell line at week 9. Quest Diagnostics (Pittsburg, PA) was utilized to transport and analyze all blood samples. Statistical Analysis Separate analyses of co-variance (ANCOVA), using baseline scores as the covariate were used to analyze between-group differences in body composition, muscular performance, and Selleck Alpelisib clinical markers of safety. Data was considered statistically significant when the probability of a type I error was less than or equal to 0.05 (P ≤ 0.05). If a significant group, treatment and/or interaction was observed,

least significant differences (LSD) post-hoc analyses were performed to locate the pair-wise differences between means. Results Demographics The demographic characteristics of the two cohorts were similar, and these are presented in Table 1. All 20 subjects were male, and the age range was 19-31 years. Glycogen branching enzyme The mean values for age, height, weight, baseline fat percentage, blood pressure and resting heart rate were similar in the

two cohorts. Table 1 Baseline Demographic Characteristics Parameter SOmaxP 95% CI Comparator (CP) 95% CI Age (years) 21.9 20.5-23.3 23.9 21.9-25.9 Height (inches) 70.7 69.0-72.4 69.8 68.3-71.3 Weight (kg) 81.1 77.3-84.9 79.9 74.2-85.6 Fat percentage 16.78 14.0-19.6 16.45 13.4-19.5 Resting Heart Rate (bpm) 60.9 56.9-64.9 66.4 59.9-73.0 Blood pressure (mm Hg) 133/76 130-136/70-82 128/79 119-136/74-84 Performance Measures A summary of the performance and outcome measures at baseline (“”Pre”") and at week 9 session (“”Post”") are presented in Table 2 and discussed below. The values are the mean values per cohort at baseline and week 9. Figure 2 displays these data using the least square mean ANCOVA analysis for 1 RM. Figure 3 displays the ANCOVA for Repititions to Failure (RTF). Figure 4 displays the ANCOVA for percent body fat. Figure 5 displays the ANCOVA for lean mass. Figure 6 displays the ANCOVA for fat mass. Statistically significant differences between the SOmaxP and CP cohorts were observed for 1 RM (p = 0.019), RTF (p = 0.004), body fat percent (p = 0.028), lean mass (p = 0.049), and fat mass (p = 0.023). Table 2 Summary of www.selleckchem.com/products/prt062607-p505-15-hcl.html Important Outcome Measures from Baseline to Week 9 (Workout session 36) Measure SOmaxP CP P-Value (ANCOVA)   Baseline Week 9 %Change Baseline Week 9 %Change p-value (difference)* 1-RM lbs (kg) 233.5 (106.